Tilray (TLRY) Competitors $0.40 -0.01 (-2.71%) As of 01:29 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TLRY vs. CRON, CDXC, MNMD, USNA, UPXI, SNDL, ACB, CGC, MDWD, and BTMDShould you be buying Tilray stock or one of its competitors? The main competitors of Tilray include Cronos Group (CRON), ChromaDex (CDXC), Mind Medicine (MindMed) (MNMD), USANA Health Sciences (USNA), Upexi (UPXI), SNDL (SNDL), Aurora Cannabis (ACB), Canopy Growth (CGC), MediWound (MDWD), and biote (BTMD). These companies are all part of the "medicinals & botanicals" industry. Tilray vs. Its Competitors Cronos Group ChromaDex Mind Medicine (MindMed) USANA Health Sciences Upexi SNDL Aurora Cannabis Canopy Growth MediWound biote Tilray (NASDAQ:TLRY) and Cronos Group (NASDAQ:CRON) are both small-cap consumer staples companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, risk, community ranking, valuation, dividends, institutional ownership, profitability, analyst recommendations and media sentiment. Which has higher valuation & earnings, TLRY or CRON? Cronos Group has lower revenue, but higher earnings than Tilray. Tilray is trading at a lower price-to-earnings ratio than Cronos Group, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTilray$210.48M1.95-$244.98M-$1.05-0.39Cronos Group$124.59M6.02-$73.96M$0.1314.96 Do analysts recommend TLRY or CRON? Tilray currently has a consensus target price of $1.92, suggesting a potential upside of 369.77%. Given Tilray's stronger consensus rating and higher possible upside, equities research analysts plainly believe Tilray is more favorable than Cronos Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tilray 0 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.25Cronos Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media refer more to TLRY or CRON? In the previous week, Tilray had 3 more articles in the media than Cronos Group. MarketBeat recorded 5 mentions for Tilray and 2 mentions for Cronos Group. Cronos Group's average media sentiment score of 1.05 beat Tilray's score of 0.63 indicating that Cronos Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tilray 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cronos Group 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is TLRY or CRON more profitable? Tilray has a net margin of -30.95% compared to Cronos Group's net margin of -42.65%. Cronos Group's return on equity of -2.56% beat Tilray's return on equity.Company Net Margins Return on Equity Return on Assets Tilray-30.95% -4.40% -3.57% Cronos Group -42.65%-2.56%-2.47% Do institutionals and insiders believe in TLRY or CRON? 9.4% of Tilray shares are held by institutional investors. Comparatively, 8.7% of Cronos Group shares are held by institutional investors. 0.6% of Tilray shares are held by insiders. Comparatively, 7.3% of Cronos Group shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Does the MarketBeat Community favor TLRY or CRON? Cronos Group received 16 more outperform votes than Tilray when rated by MarketBeat users. Likewise, 61.13% of users gave Cronos Group an outperform vote while only 59.10% of users gave Tilray an outperform vote. CompanyUnderperformOutperformTilrayOutperform Votes44859.10% Underperform Votes31040.90% Cronos GroupOutperform Votes46461.13% Underperform Votes29538.87% Which has more volatility & risk, TLRY or CRON? Tilray has a beta of 1.83, suggesting that its share price is 83% more volatile than the S&P 500. Comparatively, Cronos Group has a beta of 1.04, suggesting that its share price is 4% more volatile than the S&P 500. SummaryTilray and Cronos Group tied by winning 9 of the 18 factors compared between the two stocks. Get Tilray News Delivered to You Automatically Sign up to receive the latest news and ratings for TLRY and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TLRY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TLRY vs. The Competition Export to ExcelMetricTilrayMedicinals & botanicals IndustryStaples SectorNASDAQ ExchangeMarket Cap$409.64M$1.23B$17.50B$8.57BDividend YieldN/AN/A3.07%4.17%P/E Ratio-1.3612.9516.3519.81Price / Sales1.9511.0943.31154.51Price / CashN/A10.4016.3934.64Price / Book0.101.466.134.65Net Income-$244.98M-$56.07M$734.57M$248.05M7 Day Performance0.59%-2.24%0.07%-0.15%1 Month Performance-9.41%-0.54%-0.64%4.50%1 Year Performance-76.69%-33.28%2.28%13.76% Tilray Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TLRYTilray1.9446 of 5 stars$0.41-2.0%$1.92+369.8%-76.5%$409.64M$210.48M-1.362,650CRONCronos Group1.6895 of 5 stars$1.96-0.3%N/A-20.4%$754.01M$124.59M-15.04450Positive NewsCDXCChromaDex2.6162 of 5 starsN/A$9.03+∞N/A$611.50M$99.60M787.29120MNMDMind Medicine (MindMed)1.9298 of 5 stars$8.06+3.9%$25.50+216.4%-7.0%$608.58MN/A-3.5640Positive NewsAnalyst RevisionGap DownUSNAUSANA Health Sciences4.0427 of 5 stars$30.74+3.1%$36.00+17.1%-35.5%$572.19M$876.24M10.861,900UPXIUpexi1.0235 of 5 stars$12.12+1.0%N/A+26.9%$461.05M$16.56M0.00130Short Interest ↑SNDLSNDL3.6129 of 5 stars$1.33-0.4%$3.63+173.6%-34.1%$348.18M$927.61M-4.27580ACBAurora Cannabis0.3 of 5 stars$5.93+1.9%N/A+0.7%$332.51M$320.81M118.321,340Upcoming EarningsCGCCanopy Growth2.5611 of 5 stars$1.55-4.6%$2.00+29.4%-79.8%$284.07M$269.00M-0.413,150Positive NewsMDWDMediWound2.0686 of 5 stars$21.48+0.1%$31.80+48.0%+26.6%$232.16M$19.21M-7.4180BTMDbiote3.8941 of 5 stars$4.06+3.3%$8.00+97.0%-40.4%$221.90M$199.38M15.60194 Related Companies and Tools Related Companies CRON Competitors CDXC Competitors MNMD Competitors USNA Competitors UPXI Competitors SNDL Competitors ACB Competitors CGC Competitors MDWD Competitors BTMD Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TLRY) was last updated on 6/13/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredBanks aren’t ready for this altcoin—are you?Donald Trump just fast-tracked TWO major crypto bills with an August deadline! Your window of opportunity i...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tilray Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Tilray With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.